ClinicalTrials.gg
RecruitingNCT05167487PLANETUpdated Feb 6, 2026

Pathological Response After Neoadjuvant Treatment on NSCLC

An observational study in Stage IIIA Non-small Cell Lung Cancer, sponsored by Fundación GECP. Recruiting at 17 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Fundación GECP · Observational

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP — 8 open to participants now, 13 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Fundación GECP.

Started
2021
with 4 others
Observational
5 of 18
2 open now
Primary completion
2028-04
later than 6 of 12 live
Registered
9th of 18
by date

Among the 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP, this one is one of 5 that started in 2021, is one of 5 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP, or all of them as a file.
02

Study summary

This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical trials case report forms.

Read the detailed description

This is a non-interventional, observational, multicenter and retrospective study that will not under any circumstances interfere in the physician's normal clinical practice. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry (TTR) data base and the data from stage IIIA clinical trials case report forms, it does not entail any diagnostic or therapeutic procedure outside of normal clinical practice.

The primary objective is to assess pathological response after neoadjuvant treatment as a subrogate endpoint for overall survival and disease-free survival in resectable stage IIIA non-small cell lung cancer patients.

It is estimated that around 15-20 Spanish sites are enrolling patients with these characteristics in the TTR or in the stage IIIA clinical trials of the Fundación GECP.

Pathologists and physician's of these sites will be invited to participate in the PLANET study as all cases will be clinical-pathologically re-evaluated to reach the study objectives. Each pathologist will re-evaluate the specimens from the selected patients under common criteria.The sample size would be 150 patients enrolled in the study.

03

Conditions studied

  • Stage IIIA Non-small Cell Lung Cancer

Keywords

  • Neoadjuvant Treatment
  • Observational study
  • Resectable IIIA patients
  • Non small cell lung cancer
  • Pathological response
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include all resectable stage IIIA patients who have received platinum-based neoadjuvant treatment and surgery and that were diagnosed as stage IIIA from 2010 to 2017.The cohort of patients identified for the current study will be based on a portion of patients included in the Thoracic Tumor Registry (TTR) and in stage IIIA clinical trials approved by Spanish Health Authorities which the sponsor is Fundación GECP.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with resectable stage IIIA disease (according to American Joint Committee on Cancer [AJCC] lung cancer edition 7 or 8) who were included in the Tumor Thoracic Registry data base and in stage IIIA clinical trials which the sponsor is Fundación GECP.
  • Patients with histologically N2 involvement confirmed
  • Patients diagnosed as stage IIIA from 2010 and 2017
  • Patients who have received platinum-based treatment and surgery
  • Age ≥ 18 years at time of study entry
  • PET /TC at diagnosis

Exclusion criteria

Exclusion Criteria:

  • Patients who received chemoradiotherapy treatment
  • Patients who were not resected after neoadjuvant treatment
  • Patients who were diagnosed after June 2017
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Experimental: platinum-based neoadjuvant treatment and surgery.

    Resectable stage IIIA non-small cell lung cancer patients treated with platinum-based neoadjuvant treatment and surgery.

    Drug: Cisplatin · Drug: Carboplatin

Interventions

  • Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.

    Also known as: Cis-diammine-dichloroplatinum, Platinol

  • Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.

    Also known as: Paraplatin

06

What researchers measure

Primary outcomes

  1. To assess pathological response after neoadjuvant treatment as a subrogate endpoint for overall survival and disease-free survival in resectable stage IIIA non-small cell lung cancer patients.

    Pathological response will be assessed as complete pathological response, major pathological response (defined as ≤10% of viable tumor cells) and incomplete pathological response.

    Time frame: From the end of neoadjuvant treatment until the last follow up or death, assessed up to 45 months

Secondary outcomes

  1. To describe the percentage of residual viable tumor in this population of patients under common criteria

    A) No response or more than 70% of viable tumor: Lymph node major pathological response negative (LN-MPR)- B) ≤70% of viable tumor cells: Lymph node major pathological response positive (LN-MPR)+ C) No evidence of any viable tumor (including primary tumor): Complete pathological response

    Time frame: From the end of neoadjuvant treatment until the last follow up or death,assessed up to 45 months

  2. To describe the histopathological changes within tumor bed associated to tumor response

    Types of histopathological changes within tumor bed: fibrosis, lymphoid aggregates and others

    Time frame: From the end of neoadjuvant treatment until the last follow up or death, assessed up to 45 months

  3. To correlate pathological response and post-surgical complications

    Pathological response will be assessed as complete pathological response, major pathological response (defined as ≤10% of viable tumor cells) and incomplete pathological response.

    Time frame: From the end of neoadjuvant treatment until the last follow up or death, assessed up to 45 months

  4. To describe the relation between nodal downstaging after neoadjuvant treatment and overall survival

    Downstaging after surgery is a reduction in the stage of a cancer. Overall Survival defined as the length of time from either the date of diagnosis or the start of the treatment that patients diagnosed with the disease are still alive.

    Time frame: From the end of neoadjuvant treatment until the last follow up or death, assessed up to 45 months

07

Study locations

17 of 17 sites recruiting
  • Hospital Universitario De A Coruna
    A Coruña, A Coruña 15006, Spain
    Recruiting
    • Teresa Hermida, MD · Contact
    • Teresa Hermida, MD · Principal investigator
  • Hospital General Universitario de Alicante
    Alicante, Alicante 03010, Spain
    Recruiting
    • Ignacio Aranda, MD · Contact
    • Ignacio Aranda, MD · Principal investigator
  • ICO Badalona, Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
    Recruiting
    • José Luis Mate, MD · Contact
    • José Luis Mate, MD · Principal investigator
  • Hospital Vall d'Hebron
    Barcelona, Barcelona 08035, Spain
    Recruiting
    • Irene Sansano, MD · Contact
    • Irene Sansano, MD · Principal investigator
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Barcelona 08041, Spain
    Recruiting
    • Laura López Vilaró, MD · Contact
    • Laura López Vilaró, MD · Principal investigator
  • ICO Hospitalet
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Recruiting
    • Nuria Baixeras, MD · Contact
    • Nuria Baixeras, MD · Principal investigator
  • Hospital Universitario Insular de Gran canaria
    Las Palmas de Gran Canaria, Gran Canaria 35016, Spain
    Recruiting
    • Maria del Carmen Camacho, MD · Contact
    • Maria del Carmen Camacho, MD · Principal investigator
  • Hospital Dr. Negrín
    Las Palmas de Gran Canaria, Las Palmas 35010, Spain
    Recruiting
    • María Luz Plaza, MD · Contact
    • María Luz Plaza · Principal investigator
  • Hospital Clínico San Carlos
    Madrid, Madrid 28040, Spain
    Recruiting
    • Melchor Saiz Pardo, MD · Contact
    • Melchor Saiz Pardo, MD · Principal investigator
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, Madrid 28040, Spain
    Recruiting
    • Federico Rojo, MD · Contact
    • Federico Rojo, MD · Principal investigator
  • Hospital 12 De Octubre
    Madrid, Madrid 28041, Spain
    Recruiting
    • Ana Belén Enguita, MD · Contact
    • Ana Belén Enguita, MD · Principal investigator
  • Hospital Universitario la Paz
    Madrid, Madrid 28046, Spain
    Recruiting
    • Isabel Esteban, MD · Contact
    • Isabel Esteban, MD · Principal investigator
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
    Recruiting
    • Mariano Provencio, MD · Contact
    • Clara Salas, MD · Principal investigator
  • Hospital Universitario Regional de Málaga
    Málaga, Málaga 29010, Spain
    Recruiting
    • Pino Flores, MD · Contact
    • Pino Flores, MD · Principal investigator
  • Complejo Hospitalario Universitario de Vigo
    Vigo, Pontevedra 36036, Spain
    Recruiting
    • Ana González, MD · Contact
    • Ana González, MD · Principal investigator
  • Hospital Universitario La Fe
    Valencia, Valencia 46026, Spain
    Recruiting
    • Nuria Mancheño, MD · Contact
    • Nuria Mancheño, MD · Principal investigator
  • Hospital Universitario Cruces
    Barakaldo, Vizcaya 48903, Spain
    Recruiting
    • Mónica Saiz, MD · Contact
    • Mónica Saiz, MD · Principal investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Apr 2028, 75 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2021
First posted
Dec 22, 2021
StartActual
Dec 13, 2021
Primary completionEst.
Apr 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05167487
Lead sponsor
Fundación GECP
Responsible party
Sponsor
First posted
Dec 22, 2021
Start date
Dec 13, 2021
Primary completion
Apr 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Feb 6, 2026

Study contacts

Eva Pereira
Contact
gecp@gecp.org
+34934302006
Mariano Provencio, MD
study chair · President of Grupo Español de Cáncer de Pulmón

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion